文献速递泌尿生殖MR

AI赋能前列腺癌主动监测MRI:整合PRECISE v2、PI-QUAL与纵向生物标志物

Artificial intelligence-enabled MRI surveillance of prostate cancer: integrating PRECISE v2, PI-QUAL, and longitudinal biomarkers-a narrative review.
PubMed 文献 · Abdom Radiol (NY) · 2026-07-04

本篇为叙述性综述,围绕低危及部分预后良好中危前列腺癌主动监测展开,总结PRECISE v2序列MRI报告规范及其与PI-RADS、PI-QUAL的关系。文章梳理人工智能在前列腺MRI质控、检测、分割和纵向分析中的应用机会,并指出目前缺乏主动监测场景下的外部验证与前瞻性评价。

要点

  • PRECISE v2要求与基线及既往扫描对比,并将稳定病变细分为可见和不可见两类。
  • 图像质量未达最低阈值时报告为PRECISE-X,避免在质量不足图像上判断进展。
  • AI辅助路径目前不能用于改变活检时机,MRI应补充而非替代活检。

核心结论

  • 标准化图像质量和序列报告后,序列mpMRI可支持主动监测,但MRI应补充而非替代活检。
  • AI辅助路径需完成主动监测场景下的外部验证、校准、协调化和前瞻性评估后,才可能用于调整活检时机。

研究设计与样本

  • 本文为叙述性综述,总结PRECISE v2、其与PI-RADS和PI-QUAL的关系及AI整合策略。

诊断标准与关键数值

  • PRECISE v2引入最低质量阈值,未达标报告为PRECISE-X,不与基线比较评估。
  • PRECISE v2要求同时与基线和既往MRI比较,稳定病变细分为可见病灶3-V和不可见病灶3-NonV。

临床应用与阅片要点

  • 报告序列MRI随访时,应先评估图像质量是否达到PRECISE最低阈值,再判断有无影像学进展。
  • 阅片时需分别与基线及最近一次检查对比,避免仅与某一次检查比较造成进展误判。
  • 测量病变径线时尽量利用分割和病灶追踪减少观察者间差异,并结合PSA密度及动力学变化综合判断。

局限性

  • AI应用存在数据集偏移、样本量不均衡、进展标签不完善和外部验证有限等障碍。
  • 放射组学特征不稳定、校准不足、缺失数据及不确定性量化欠缺限制当前临床转化。
  • AI辅助主动监测路径尚缺乏前瞻性评估,暂不能据此修改活检频率或时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Active surveillance (AS) is widely used for men with low-risk and selected favorable intermediate-risk prostate cancer, but pathways remain heterogeneous and often rely on serial biopsy despite sampling limitations and morbidity. Multiparametric MRI (mpMRI) improves enrollment and longitudinal monitoring, yet reproducibility depends on image quality, reader expertise, measurement consistency, biopsy quality, and clear definitions of progression. The PRECISE recommendations were developed to standardize serial MRI reporting, and PRECISE version 2 (PRECISE v2) introduces key refinements, including minimum quality thresholds (PRECISE-X), comparison with both baseline and prior scans, and subdivision of stable examinations into visible and non-visible disease (3-V and 3-NonV). In parallel, artificial intelligence (AI) for prostate MRI is advancing in quality control, detection, segmentation, and longitudinal analysis. Near-term opportunities in AS include automated quality checks, reduction of measurement variability through segmentation and lesion tracking, and integration of imaging change with clinical and biomarker trajectories such as PSA density and kinetics. However, key barriers include dataset shift, sample-size imbalance, imperfect progression labels, limited external validation, radiomic feature instability, calibration, missing data, uncertainty quantification, and the need for transparent human-AI interaction. This narrative review summarizes PRECISE v2, its relationship with PI-RADS and PI-QUAL, and emerging strategies to combine PRECISE-aligned imaging change with longitudinal clinical and biomarker information for risk-adapted decision support. Serial mpMRI can support AS when image quality and serial reporting are standardized; however, MRI should complement rather than replace biopsy, and AI-assisted pathways require AS-specific external validation, calibration, harmonization, and prospective evaluation before they can be used to modify biopsy timing.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Fujiwara, Pakpoor, Aslan, et al. Artificial intelligence-enabled MRI surveillance of prostate cancer: integrating PRECISE v2, PI-QUAL, and longitudinal biomarkers-a narrative review. Abdom Radiol (NY). 2026. PMID: 42400610. doi:10.1007/s00261-026-05634-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。